$1–$10 Watch: 10 Stocks That Could Explode — October 5, 2026

$1–$10 Watch: 10 Stocks That Could Explode — October 5, 2026

Low-priced stocks often present unique opportunities for explosive returns. Here’s a look at ten specific stocks currently trading between $1 and $10 that could see significant upside over the next few months.

1. SNDL - Sundial Growers Inc. - **Current Price:** $1.25 - **Sector:** Cannabis - **Volume Profile:** Increasing volume indicates accumulation as retail interest grows. - **Short Interest:** 30% — high short interest suggests potential for a short squeeze. - **Catalyst:** Regulatory changes in cannabis legislation could drive demand. - **Technical Setup:** Recently bounced off $1.00 support level. - **Risk Factors:** Continued regulatory uncertainty in the cannabis sector. - **Bull Case Price Target:** $2.00 (60 days) - **Risk Rating:** 🟡 High

2. CLOV - Clover Health Investments Corp. - **Current Price:** $2.10 - **Sector:** Healthcare - **Volume Profile:** Steady increase in trading volume, indicating growing investor interest. - **Short Interest:** 25% — potential for a squeeze if fundamentals improve. - **Catalyst:** Upcoming earnings report could beat expectations. - **Technical Setup:** Forming a bullish flag pattern. - **Risk Factors:** Competition in the healthcare space could threaten market share. - **Bull Case Price Target:** $3.50 (45 days) - **Risk Rating:** 🟡 High

3. MVIS - MicroVision, Inc. - **Current Price:** $4.00 - **Sector:** Technology - **Volume Profile:** Recent spikes in volume suggest growing investor interest. - **Short Interest:** 20% — could be a candidate for a short squeeze. - **Catalyst:** Expected product launches in LiDAR technology could attract attention. - **Technical Setup:** Breaking out of a consolidation pattern above $3.50. - **Risk Factors:** Heavy reliance on successful product development. - **Bull Case Price Target:** $6.50 (60 days) - **Risk Rating:** 🟡 High

4. ZOM - Zomedica Corp. - **Current Price:** $1.75 - **Sector:** Veterinary Health - **Volume Profile:** Increasing volume as new product launches are anticipated. - **Short Interest:** 35% — high short interest could lead to a squeeze. - **Catalyst:** Launch of new diagnostics products for pets. - **Technical Setup:** Testing support at $1.50. - **Risk Factors:** Uncertainty in regulatory approvals for products. - **Bull Case Price Target:** $3.00 (90 days) - **Risk Rating:** 🟡 High

5. ATER - Aterian, Inc. - **Current Price:** $6.90 - **Sector:** Consumer Goods - **Volume Profile:** Volume increasing, indicating accumulation. - **Short Interest:** 40% — high potential for a short squeeze. - **Catalyst:** New product lines and expansion into e-commerce. - **Technical Setup:** Recently broke out of a descending triangle. - **Risk Factors:** High competition in the consumer goods sector. - **Bull Case Price Target:** $9.00 (60 days) - **Risk Rating:** 🟡 High

6. HCMC - Healthier Choices Management Corp. - **Current Price:** $0.12 - **Sector:** Health & Wellness - **Volume Profile:** Volume spikes indicate speculative interest. - **Short Interest:** 15% — lower than others, but still significant. - **Catalyst:** Ongoing intellectual property litigation could drive interest. - **Technical Setup:** Testing support at $0.10. - **Risk Factors:** Legal outcomes are unpredictable. - **Bull Case Price Target:** $0.25 (90 days) - **Risk Rating:** 🔴 Very High

7. OCGN - Ocugen, Inc. - **Current Price:** $1.90 - **Sector:** Biopharmaceutical - **Volume Profile:** Increasing volume indicates renewed interest. - **Short Interest:** 22% — potential for short covering. - **Catalyst:** FDA approval of Covid-19 vaccine candidate. - **Technical Setup:** Recently bounced off $1.50 support level. - **Risk Factors:** Regulatory delays could impact stock performance. - **Bull Case Price Target:** $3.00 (60 days) - **Risk Rating:** 🟡 High

8. GME - GameStop Corp. - **Current Price:** $7.50 - **Sector:** Retail - **Volume Profile:** Significant volume spikes during earnings season. - **Short Interest:** 18% — potential for a short squeeze. - **Catalyst:** Continued growth in e-commerce strategies. - **Technical Setup:** Testing resistance at $8.00. - **Risk Factors:** Market volatility and competition from digital platforms. - **Bull Case Price Target:** $10.00 (30 days) - **Risk Rating:** 🟡 High

9. AEZS - Aeterna Zentaris Inc. - **Current Price:** $1.05 - **Sector:** Biotechnology - **Volume Profile:** Increasing volume suggests accumulation. - **Short Interest:** 28% — high potential for a short squeeze. - **Catalyst:** New trial data for cancer drugs could attract attention. - **Technical Setup:** Recently bounced off $1.00 support. - **Risk Factors:** Dependence on trial results can be risky. - **Bull Case Price Target:** $2.00 (60 days) - **Risk Rating:** 🟡 High

10. GTT - GTT Communications, Inc. - **Current Price:** $4.50 - **Sector:** Telecommunications - **Volume Profile:** Increased volume as restructuring efforts gain traction. - **Short Interest:** 30% — possible short squeeze opportunity. - **Catalyst:** Successful completion of restructuring plan could improve fundamentals. - **Technical Setup:** Bouncing off a recent low at $4.00. - **Risk Factors:** Execution risks in restructuring. - **Bull Case Price Target:** $7.00 (90 days) - **Risk Rating:** 🟡 High

Why These Price Ranges Matter Stocks in the $1 to $10 range often have low floats, making them more susceptible to volatility and rapid price movements. This volatility can lead to significant gains, particularly when the market sentiment is favorable or a catalyst presents itself. Investors can capitalize on these price movements with careful analysis and timing.

How to Trade Them Safely When trading low-priced stocks, consider position sizing carefully. Avoid overcommitting capital to any single trade, and use limit orders to ensure you enter at favorable prices. Stay aware of catalyst timings, as these can lead to abrupt shifts in stock performance.

Catalyst Calendar - **CLOV:** Earnings report on October 15, 2026 - **SNDL:** Legislative updates expected in November 2026 - **OCGN:** FDA decision anticipated by November 2026

Educational content only. Not financial advice. DYOR.